Education
About Us
Working with TipRanks
Follow Us
Nanjing Leads Biolabs Co., Ltd. Class H (HK:9887)
:9887
9887 Stock Chart & Stats
HK$55.70
--
Market closed
HK$55.70
--
Day’s Range― - ―
52-Week RangeHK$44.72 - HK$83.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)731.14K
Market Cap
HK$11.24B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding153,278,690
10 Day Avg. Volume688,690
30 Day Avg. Volume731,143
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$98.78Price Target Upside77.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nanjing Leads Biolabs Co., Ltd. Class H News
9887 FAQ
What was Nanjing Leads Biolabs Co., Ltd. Class H’s price range in the past 12 months?
Nanjing Leads Biolabs Co., Ltd. Class H lowest stock price was HK$44.72 and its highest was HK$83.60 in the past 12 months.
What is Nanjing Leads Biolabs Co., Ltd. Class H’s market cap?
Nanjing Leads Biolabs Co., Ltd. Class H’s market cap is HK$11.24B.
When is Nanjing Leads Biolabs Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nanjing Leads Biolabs Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Nanjing Leads Biolabs Co., Ltd. Class H overvalued?
According to Wall Street analysts Nanjing Leads Biolabs Co., Ltd. Class H’s price is currently Undervalued.
Does Nanjing Leads Biolabs Co., Ltd. Class H pay dividends?
Nanjing Leads Biolabs Co., Ltd. Class H does not currently pay dividends.
What is Nanjing Leads Biolabs Co., Ltd. Class H’s EPS estimate?
Nanjing Leads Biolabs Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanjing Leads Biolabs Co., Ltd. Class H have?
Nanjing Leads Biolabs Co., Ltd. Class H has 153,278,690 shares outstanding.
What happened to Nanjing Leads Biolabs Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanjing Leads Biolabs Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9887
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanjing Leads Biolabs Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-159.47%
Trailing 12-Months
Asset Growth
35.29%
Trailing 12-Months
Company Description
Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company's lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody. The company also develops antibody drugs for anti-tumor, autoimmune and infectious diseases and establishes tumor immunoassay. The company was founded in 2012 and is headquartered in Nanjing, China.
9887 Stock 12 Month Forecast
Average Price Target
HK$98.78
▲(77.34% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Viva Biotech Holdings
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―